SE413139B - Forfarande for framstellning av 11-cis-13-desmetyl-vitamin-a-syra - Google Patents

Forfarande for framstellning av 11-cis-13-desmetyl-vitamin-a-syra

Info

Publication number: SE413139B
Authority: SE; Sweden
Prior art keywords: acid; cis; vitamin; desmethylvitamin; formula
Prior art date: 1974-12-03

Application number

SE7513080A

Other languages

English (en)

Swedish (sv)

Other versions

SE7513080L (sv

Inventor

H Scholz

H Koenig

J Paust

W-W Wiersdorff

W Blechschmidt

R Kretzschmar

E Christophers

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-12-03

Filing date

1975-11-20

Publication date

1980-04-21

1975-11-20 Application filed by Basf Ag filed Critical Basf Ag

1976-06-04 Publication of SE7513080L publication Critical patent/SE7513080L/xx

1980-04-21 Publication of SE413139B publication Critical patent/SE413139B/sv

Links

238000000034 method Methods 0.000 title claims description 6
239000002253 acid Substances 0.000 claims description 31
-1 halide ion Chemical class 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
238000000926 separation method Methods 0.000 claims description 7
239000002585 base Substances 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical group 0.000 claims description 2
150000001449 anionic compounds Chemical class 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
239000012442 inert solvent Substances 0.000 claims description 2
229910001412 inorganic anion Inorganic materials 0.000 claims description 2
238000007127 saponification reaction Methods 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims description 2
150000002891 organic anions Chemical class 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
239000000243 solution Substances 0.000 description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
238000003756 stirring Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
229930002330 retinoic acid Natural products 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
239000000499 gel Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000004359 castor oil Substances 0.000 description 5
235000019438 castor oil Nutrition 0.000 description 5
230000000694 effects Effects 0.000 description 5
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
230000000699 topical effect Effects 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
229920002125 Sokalan® Polymers 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000007547 defect Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000002304 perfume Substances 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
150000003902 salicylic acid esters Chemical class 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
JGEMYUOFGVHXKV-OWOJBTEDSA-N fumaraldehyde Chemical compound O=C\C=C\C=O JGEMYUOFGVHXKV-OWOJBTEDSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000005662 Paraffin oil Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003480 eluent Substances 0.000 description 2
210000001339 epidermal cell Anatomy 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
101100438180 Schizosaccharomyces pombe (strain 972 / ATCC 24843) caf5 gene Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
150000001983 dialkylethers Chemical class 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
150000002829 nitrogen Chemical class 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000004080 punching Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
125000004436 sodium atom Chemical group 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Birds (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SE7513080A 1974-12-03 1975-11-20 Forfarande for framstellning av 11-cis-13-desmetyl-vitamin-a-syra SE413139B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19742456959 DE2456959A1 (de)	1974-12-03	1974-12-03	4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen

Publications (2)

Publication Number	Publication Date
SE7513080L SE7513080L (sv)	1976-06-04
SE413139B true SE413139B (sv)	1980-04-21

Family

ID=5932289

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7513080A SE413139B (sv)	1974-12-03	1975-11-20	Forfarande for framstellning av 11-cis-13-desmetyl-vitamin-a-syra

Country Status (7)

Country	Link
BE (1)	BE835902A (fr)
CH (1)	CH619211A5 (fr)
DE (1)	DE2456959A1 (fr)
FR (1)	FR2293193A1 (fr)
GB (1)	GB1526410A (fr)
SE (1)	SE413139B (fr)
ZA (1)	ZA757545B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2843811A1 (de) *	1978-10-07	1980-04-24	Basf Ag	Retinsaeure- und 7,8-dehydro-retinsaeure-n-(carboxy)-phenylamide
WO1982002833A1 (fr) *	1981-02-17	1982-09-02	Gail Sansone Bazzano	Utilisation de retinoides et de leur derive pour accroitre le taux de croissance des cheveux humains et pour accroitre le taux de croissance de la fourrure chez certains animaux a fourrure
WO1983002558A1 (fr) *	1981-11-09	1983-08-04	Gail Sansone Bazzano	Utilisation de retinoides et minoxydile (2,4,-diamino-6-piperidino-pyrimidine-3-oxyde) pour ameliorer le taux de croissance des cheveux et traiter certains types d'alopecies chez l'homme
CH651007A5 (de) *	1982-06-24	1985-08-30	Hoffmann La Roche	Polyenverbindungen.
US4539154A (en) *	1983-06-15	1985-09-03	Hoffmann-La Roche Inc.	Polyene compounds
US4743400A (en) *	1986-09-22	1988-05-10	Mcneilab, Inc.	Process for preparing retinoyl chlorides
US7655699B1 (en)	1992-04-22	2010-02-02	Eisai Inc.	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5962731A (en) *	1992-04-22	1999-10-05	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) *	1992-04-22	1998-07-14	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ES2129115T3 (es) *	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
ATE191444T1 (de) *	1993-12-15	2000-04-15	Avon Prod Inc	Neue retinoidkonjugate zur behandlung von alterserscheinungen der haut
EP3326623A1 (fr)	2003-03-14	2018-05-30	University of Washington	Remplacements de rétinoïdes et agonistes de l'opsine et leurs procédés d'utilisation
US7566808B2 (en)	2004-02-17	2009-07-28	President And Fellows Of Harvard College	Management of ophthalmologic disorders, including macular degeneration
NZ587006A (en)	2004-06-18	2011-12-22	Univ Washington	11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2009102418A1 (fr)	2008-02-11	2009-08-20	University Of Washington	Procédés pour le traitement et la prévention d'un dysfonctionnement rétinien lié à l'âge
CN102612375B (zh)	2009-09-15	2016-01-27	Qlt股份有限公司	含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
CN107308143A (zh)	2010-04-19	2017-11-03	诺维利昂治疗股份有限公司	用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
JP6576636B2 (ja)	2012-03-01	2019-09-18	ノベリオンセラピューティクスインコーポレイテッド	内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法

1974
- 1974-12-03 DE DE19742456959 patent/DE2456959A1/de not_active Withdrawn
1975
- 1975-11-20 SE SE7513080A patent/SE413139B/sv unknown
- 1975-11-25 BE BE162142A patent/BE835902A/fr not_active IP Right Cessation
- 1975-12-01 CH CH1559775A patent/CH619211A5/de not_active IP Right Cessation
- 1975-12-02 GB GB49370/75A patent/GB1526410A/en not_active Expired
- 1975-12-02 FR FR7536850A patent/FR2293193A1/fr active Granted
- 1975-12-02 ZA ZA00757545A patent/ZA757545B/xx unknown

Also Published As

Publication number	Publication date
DE2456959A1 (de)	1976-06-16
GB1526410A (en)	1978-09-27
SE7513080L (sv)	1976-06-04
BE835902A (fr)	1976-05-25
FR2293193B1 (fr)	1979-09-21
ZA757545B (en)	1976-12-29
CH619211A5 (en)	1980-09-15
FR2293193A1 (fr)	1976-07-02

Publication	Publication Date	Title
SE413139B (sv)	1980-04-21	Forfarande for framstellning av 11-cis-13-desmetyl-vitamin-a-syra
US4694090A (en)	1987-09-15	Chroman compounds useful as analgerics and antioxidants
GB2143528A (en)	1985-02-13	Salts of 2-(2,6-dichloroanilino)-phenyl acetic acid
HU193815B (en)	1987-12-28	Process for preparing tetraline derivatives
DK159148B (da)	1990-09-10	Analogifremgangsmaade til fremstilling af tranexamsyrederivater
KR0145525B1 (ko)	1998-08-17	지방족 2-히드록시산을 갖는 1-벤질-3-히드록시메틸-인다졸의 에테르
JP2603620B2 (ja)	1997-04-23	エイコサトリインアミド−５，８，１１化合物，その製造方法および医薬品組成物
US4213978A (en)	1980-07-22	Anti-acne and anti-seborrhea prodrug derivatives of progesterone
EP0643701B1 (fr)	2001-12-05	Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique
KR950006891B1 (ko)	1995-06-26	아미노 알코올의 제조방법
EP0203435A2 (fr)	1986-12-03	Dérivés de pyridine et leur procédé de préparation
CA1127170A (fr)	1982-07-06	N-(carboxy)-phenylamides de l'acide retinique et n-(carboxy)-phenylamides de l'acide 7,8-dehydro- retinique, leur preparation, et formulations pharmaceutiques qui en contiennent
US4451473A (en)	1984-05-29	3,7-Diazabicyclo [3.3.1] nonanes having anti-arrhythmic activity
GB2118554A (en)	1983-11-02	N-carbamoyl derivatives of isothiazolo (5,4b)-pyridin-3-one
CA1143657A (fr)	1983-03-29	Agent pharmaceutique contenant de l'acide e-ou 13-z-7,8-dehydroretinique, methode de preparation et utilisation
EP0009776B1 (fr)	1982-07-28	N-monohydroxypropylamides, N-dihydroxypropylamides et leurs acetonoides de l'acide all-E et 13-Z rétinoique, procédé pour leur préparation et compositions pharmaceutiques les contenant
IE50767B1 (en)	1986-07-09	5-amino-tetrazole derivatives of retinoic acids,their preparation,and pharmaceutical formulations containing these derivatives
US4060638A (en)	1977-11-29	Anthranilic acid amides
KR880001863B1 (ko)	1988-09-23	사이클로헵텐 유도체의 제조방법
JPS636548B2 (fr)	1988-02-10
US3792082A (en)	1974-02-12	Esters of halophenoxyisobutyric acid and hydroxy-aliphatic acid derivatives
IL28867A (en)	1972-04-27	1-adamantyl and 1-adamantylmethyl carbonates of testosterone and derivatives thereof
JPS62116545A (ja)	1987-05-28	殺菌性ωアミノアルカノ−ル置換芳香族誘導体、その製造方法およびそれを含む組成物
EP0135406A1 (fr)	1985-03-27	Pyrrolidinones actives sur le système nerveux central, leur procédé de préparation, les médicaments en contenant
EP0149588A2 (fr)	1985-07-24	N-(naphtyl-alkyl)-hydroxylamines